Merck KGaA hopes for stable 2010 for continued revenue growth
This article was originally published in Scrip
Executive Summary
Merck KGaA's 2009 revenues increased by 2% to €7.7 billion on the back of strong pharmaceutical sales, but its after-tax profits were hurt by higher R&D costs and the amortisation of intangible assets.